부산대학교 도서관

To authenticate to the full-text of this article, please visit this link: http://dx.doi.org/10.1111/j.1365-2230.2008.02985.x Byline: L. Timmer-de Mik, S. H. Kardaun (*), M. H. H. Kramer ([dagger]), D. P. Hayes ([dagger][double dagger]), M. T. Bousema Abstract: Summary Imatinib, a synthetic tyrosine kinase inhibitor, is used as first-line therapy for chronic myeloid leukaemia. Imatinib treatment is associated with a variety of adverse effects, most of which are mild to moderate and generally abate after the first months of treatment. Cutaneous adverse reactions are often encountered in patients using imatinib. Pseudoporphyria is regularly associated with the use of medication, especially naproxen and other nonsteroidal anti-inflammatory drugs, but the list of culprits is expanding. We present a patient with imatinib-induced pseudoporphyria. Taking into account the rapidly growing use of imatinib, physicians should be aware of the possibility of imatinib-induced pseudoporphyria. Adequate photoprotection can improve treatment compliance. Author Affiliation: Departments of Dermatology ([dagger])Internal Medicine ([double dagger])Pathology, Meander Medical Center, Amersfoort, The Netherlands (*)Department of Dermatology, University Medical Center Groningen, University of Groningen, Center for Blistering Diseases, Groningen, The Netherlands Article History: Accepted for publication 9 June 2008 First two authors contributed equally to this work Article note: Dr Mente T. Bousema, Department of Dermatology, Meander Medical Center, PO Box 1502, 3800 BM, Amersfoort, The Netherlands., E-mail: mt.bousema@meandermc.nl